NCT02955550View on ClinicalTrials.gov

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 5, 2017

Primary Completion Date

July 10, 2018

Study Completion Date

June 4, 2019

Conditions
Multiple Myeloma
Interventions
DRUG

rhIL-2

Human recombinant Interleukin-2

BIOLOGICAL

PNK-007

PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.

Trial Locations (7)

10029

Mt. Sinai School of Medicine, New York

14263

Roswell Park Cancer Institute, Buffalo

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

63110

Washington Univ School of Medicine Siteman Cancer Center, St Louis

68198-6805

University of Nebraska Medical Center, Omaha

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Celularity Incorporated

INDUSTRY

NCT02955550 - A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) | Biotech Hunter | Biotech Hunter